Vettermann Franziska J, Diekmann Caroline, Weidner Lorraine, Unterrainer Marcus, Suchorska Bogdana, Ruf Viktoria, Dorostkar Mario, Wenter Vera, Herms Jochen, Tonn Jörg-Christian, Bartenstein Peter, Riemenschneider Markus J, Albert Nathalie L
Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany.
EJNMMI Res. 2021 Dec 14;11(1):124. doi: 10.1186/s13550-021-00865-9.
O-(2-[F]-fluoroethyl)-L-tyrosine (F-FET) is a highly sensitive PET tracer for glioma imaging, and its uptake is suggested to be driven by an overexpression of the L-type amino-acid transporter 1 (LAT1). However, 30% of low- and 5% of high-grade gliomas do not present enhanced F-FET uptake at primary diagnosis ("F-FET-negative gliomas") and the pathophysiologic basis for this phenomenon remains unclear. The aim of this study was to determine the expression of LAT1 in a homogeneous group of newly diagnosed F-FET-negative gliomas and to compare them to a matched group of F-FET-positive gliomas. Forty newly diagnosed IDH-mutant astrocytomas without 1p/19q codeletion were evaluated (n = 20 F-FET-negative (tumour-to-background ratio (TBR) < 1.6), n = 20 F-FET-positive gliomas (TBR > 1.6)). LAT1 immunohistochemistry (IHC) was performed using SLC7A5/LAT1 antibody. The percentage of LAT1-positive tumour cells (%) and the staining intensity (range 0-2) were multiplied to an overall score (H-score; range 0-200) and correlated to PET findings as well as progression-free survival (PFS).
IHC staining of LAT1 expression was positive in both, F-FET-positive as well as F-FET-negative gliomas. No differences were found between the F-FET-negative and F-FET-positive group with regard to percentage of LAT1-positive tumour cells, staining intensity or H-score. Interestingly, the LAT1 expression showed a significant negative correlation with the PFS (p = 0.031), whereas no significant correlation was found for TBR, neither in the overall group nor in the F-FET-positive group only (p = 0.651 and p = 0.140).
Although LAT1 is reported to mediate the uptake of F-FET into tumour cells, the levels of LAT1 expression do not correlate with the levels of F-FET uptake in IDH-mutant astrocytomas. In particular, the lack of tracer uptake in F-FET-negative gliomas cannot be explained by a reduced LAT1 expression. A higher LAT1 expression in IDH-mutant astrocytomas seems to be associated with a short PFS. Further studies regarding mechanisms influencing the uptake of F-FET are necessary.
O-(2-[F]-氟乙基)-L-酪氨酸(F-FET)是一种用于胶质瘤成像的高灵敏度正电子发射断层扫描(PET)示踪剂,其摄取被认为是由L型氨基酸转运体1(LAT1)的过表达驱动的。然而,30%的低级别胶质瘤和5%的高级别胶质瘤在初次诊断时未表现出F-FET摄取增强(“F-FET阴性胶质瘤”),这一现象的病理生理基础仍不清楚。本研究的目的是确定一组新诊断的F-FET阴性胶质瘤中LAT1的表达情况,并将其与一组匹配的F-FET阳性胶质瘤进行比较。对40例新诊断的异柠檬酸脱氢酶(IDH)突变型星形细胞瘤且无1p/19q共缺失的患者进行了评估(n = 20例F-FET阴性(肿瘤与本底比值(TBR)< 1.6),n = 20例F-FET阳性胶质瘤(TBR > 1.6))。使用SLC7A5/LAT1抗体进行LAT1免疫组织化学(IHC)检测。将LAT1阳性肿瘤细胞的百分比(%)和染色强度(范围0 - 2)相乘得到一个总分(H评分;范围0 - 200),并与PET结果以及无进展生存期(PFS)相关联。
LAT1表达的IHC染色在F-FET阳性和F-FET阴性胶质瘤中均为阳性。在LAT1阳性肿瘤细胞百分比、染色强度或H评分方面,F-FET阴性组和F-FET阳性组之间未发现差异。有趣的是,LAT1表达与PFS呈显著负相关(p = 0.031),而对于TBR,在整个组中以及仅在F-FET阳性组中均未发现显著相关性(p = 0.651和p = 0.140)。
尽管据报道LAT1介导F-FET进入肿瘤细胞,但在IDH突变型星形细胞瘤中,LAT1的表达水平与F-FET的摄取水平不相关。特别是,F-FET阴性胶质瘤中示踪剂摄取的缺乏不能用LAT1表达降低来解释。IDH突变型星形细胞瘤中较高的LAT1表达似乎与较短的PFS相关。有必要对影响F-FET摄取的机制进行进一步研究。